Meeting
2023 ASCO Breakthrough
Diagnostic performance of a novel radiomic model for predicting post-treatment prostate cancer recurrence: A comparison to CAPRA and MSKCC nomograms.
Authors
Linda My Huynh
University of Nebraska Medical Center, Omaha, NE
Linda My Huynh , Olivia Taylor , Jacob Marasco , Shuo Wang , Michael Baine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics
Sub Track
Omics for precision medicine
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 76)
DOI
10.1200/GO.2023.9.Supplement_1.76
Abstract #
76
Poster Bd #
E2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
A randomized phase II trial of neoadjuvant chemokine modulation in patients with localized prostate cancer undergoing radical prostatectomy.
First Author: Karan Jatwani
Poster
2021 Genitourinary Cancers Symposium
Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
First Author: Tian Zhang
Poster
2020 ASCO Virtual Scientific Program
RTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery.
First Author: Edwin Melencio Posadas
Poster
2019 ASCO Annual Meeting
A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR).
First Author: Tian Zhang